secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001759425-24-000017
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum Q1 revenue $69.2M, up 119% YoY; reaffirms FY guidance $310-320M
---------------------------------------------------------------------

- Global product sales net $68.9M, up 137% vs Q1 2023; LIVMARLI net sales $42.8M (+47%).
- FDA approved LIVMARLI for PFIC cholestatic pruritus in March 2024.
- Volixibat interim analyses (VISTAS/VANTAGE) expected June 2024; CHENODAL NDA for CTX on track H1 2024.
- Cash and equivalents $302.8M as of March 31, 2024, up from $286.3M at year-end 2023.
- Operating expenses $95.7M (incl. $17.1M non-cash items) vs $58.7M in prior-year quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942524000017/0001759425-24-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942524000017/mirm-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001759425-24-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer